The inconsistencies in reported ARB effects on the brain content of Aβ and neprilysin may possibly be explained by variability in the extent of Aβ pathology across different transgenic and chemically induced AD-like models at different ages, as well as different delivery routes used (systemic vs. intranasal). Here, MME is linked to Alzheimer disease.